In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

Zusduri is expected to be available on or around July 1, 2025. The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade ...

Despite current treatment after transurethral resection of a bladder tumor, recurrences and progression remain a problem. Keyhole limpet hemocyanin (KLH) was beneficial in earlier studies. In this ...

UGN-102 achieved a 78% complete response rate at 3 months in the phase 3 ENVISION trial for recurrent low-grade NMIBC. The FDA's Oncologic Drugs Advisory Committee narrowly voted against the ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

To reduce papillary tumor recurrence, optimized intravesical mitomycin C combined with fluorescence blue-light cystoscopy shows promise. Fluorescence blue-light cystoscopy along with optimized ...

The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin formulation is ...

Approval of Zusduri was based on data from the Phase III ENVISION trial, which showed a 78% complete response at three months in patients with recurrent low-grade, intermediate-risk non-muscle ...

Intravesical chemotherapy involves a healthcare professional injecting chemotherapy medication directly into the bladder to treat cancerous tumors. “Intravesical” means “within the bladder.” ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...